X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, LianBio will assign to Janssen exclusive rights to develop and commercialize first-in-class radio enhancer NBTXR3 (hafnium oxide) in China, South Korea, Singapore, and Thailand for the treatment of locally advanced head and neck squamous cell cancers.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 26, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Under the agreement, BMS has obtained LianBio’s exclusive rights for Camzyos (mavacamten), the first and only cardiac myosin inhibitor approved, in Mainland China and Asia for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 24, 2023
Details:
BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung cancer with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023
Details:
Camzyos (mavacamten), a cardiac myosin inhibitor, recently got approved in Macau for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tarsus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: BGJ398
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: QED Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Camzyos (mavacamten) is a cardiac myosin inhibitor, got recently approved in Macau fot the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
MYK-461 (mavacamten) is a cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic new york heart association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
